Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Study (n=478) reported improved glycaemic control at 40 weeks with all doses of tirzepatide (baseline differences vs placebo: −1.91%, −1.93% & −2.11% with 5mg, 10mg and 15 mg, respectively; all p<0.0001) and improvements in bodyweight, without increased risk of hypoglycaemia.

Source:

The Lancet